According to a story from BioPortfolio, the biopharmaceutical company AlzProtect recently announced that PAREXEL Biotech, which is a subsidiary of PAREXEL International Corporation, will be expected to conduct a Phase 2a clinical trial for an experimental drug in development from AlzProtect. The drug in question is known as AZP2006, which is being developed as a therapy for the rare disease progressive supranuclear palsy (PSP). AlzProtect is primarily focused on developing treatments for Alzheimer’s disease.
About Progressive Supranuclear Palsy (PSP)
Progressive supranuclear palsy is a type of neurodegenerative disease which is most characterized by the deterioration and death of certain areas of the brain over time. Men and women appear to affected at equal rates. There is not much known about progressive supranuclear palsy; the cause of the illness remains unknown. There is only limited evidence of genes playing a role, and current research is focusing on the role of environmental factors. Symptoms include falling, bumping into other objects, a distinctive lunging movement when walking begins, vision problems, slowing of movements, vision problems, cognitive impairment, and dystonia affecting the neck. There is no cure, and treatment is primarily supportive; management includes physical therapy to delay loss of mobility. In some cases, the Parkinson’s drug levidopa can be effective. Average survival from onset is seven years, but this varies considerably. To learn more about progressive supranuclear palsy, click here.
About The Partnership
The partnership brings together the potential impact of AlzProtect’s experimental therapy and decades of experienced personnel from PAREXEL who will serve to fill the gaps in expertise that will be needed for the successful conduct of the trial. The specific details of how this trial will be conducted have yet to be released to the public at this juncture.
AZP2006 is currently the lead drug product candidate from AlzProtect. This experimental therapy has a unique action mechanism and is classified as a bioavailable neurotrophic inducer. The drug is intended to target all possible mechanisms of neurodegeneration found in Alzheimer’s and in progressive supranuclear palsy. The experimental drug has earned orphan drug status both from the European Medicines Agency in the EU and from the US Food and Drug Administration (FDA). Earlier trials have demonstrated an absence of adverse effects and excellent tolerability in human subjects.